| Identification | Back Directory | [Name]
Acetamide, 2-[4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-N-methyl- | [CAS]
2128258-47-7 | [Synonyms]
Acetamide, 2-[4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-N-methyl- | [Molecular Formula]
C21H27NO3 | [MOL File]
2128258-47-7.mol | [Molecular Weight]
341.44 |
| Chemical Properties | Back Directory | [Boiling point ]
561.4±50.0 °C(Predicted) | [density ]
1.091±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
10.30±0.30(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
Sob-AM2 is a potent substrate (Km=1.3 μM) targeting fatty acid amide hydrolase (FAAH) expressed in the brain and has blood-brain barrier permeability. Sob-AM2 delivers high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ). In addition, Sob-AM2 can prevent myelin and axon degeneration in experimental autoimmune encephalomyelitis (EAE) mice[1]. | [References]
[1] Meinig J M, et al. Targeting fatty-acid amide hydrolase with prodrugs for CNS-selective therapy[J]. ACS chemical neuroscience, 2017, 8(11): 2468-2476. DOI:10.1021/acschemneuro.7b00239 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|